BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Classen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021;100:1603-20. [PMID: 33846857 DOI: 10.1007/s00277-021-04452-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A, Scholl S. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol 2023;149:1569-83. [PMID: 35583829 DOI: 10.1007/s00432-022-03995-2] [Reference Citation Analysis]
2 Xia S, Gong H, Wang Y, Liu L, Zhao Y, Guo L, Zhang B, Sarangdhar M, Noguchi Y, Yan M. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1129730] [Reference Citation Analysis]
3 Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, Alozie MC, Oviedo HH, Gonzalez AK, Ilangovan T, Mangubat-Medina A, Wang H, Jo E, Rabik CA, Bocchini C, Hilsenbeck S, Ball ZT, Cooper TM, Redell MS. Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers (Basel) 2023;15. [PMID: 36831684 DOI: 10.3390/cancers15041344] [Reference Citation Analysis]
4 Shah N, Mustafa SS, Vinh DC. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Crit Rev Oncol Hematol 2023;181:103896. [PMID: 36528276 DOI: 10.1016/j.critrevonc.2022.103896] [Reference Citation Analysis]
5 Nasr M, Mohammad A, Hor M, Baradeiya AM, Qasim H. Exploring the Differences in Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients. Cureus 2022. [DOI: 10.7759/cureus.27727] [Reference Citation Analysis]
6 Mellinghoff SC, Stemler J, Forkl S, Khatamzas E, Classen AY. [Management of infection in immunocompromised patients]. Dtsch Med Wochenschr 2022;147:840-50. [PMID: 35785782 DOI: 10.1055/a-1684-6763] [Reference Citation Analysis]
7 Kolbrink B, Scheikholeslami-sabzewari J, Borzikowsky C, von Samson-himmelstjerna FA, Ullmann AJ, Kunzendorf U, Schulte K. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany. The Lancet Regional Health - Europe 2022. [DOI: 10.1016/j.lanepe.2022.100400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Abad RF, Pérez-garcía A, Pestaña MÍ. Indicaciones para la prevención de infecciones en el paciente inmunocomprometido. Medicine - Programa de Formación Médica Continuada Acreditado 2022;13:3322-3326. [DOI: 10.1016/j.med.2022.05.017] [Reference Citation Analysis]
9 Hakamifard A, Mardani M, Nasiri MJ, Gholipur‐shahraki T. Bendamustine and pneumocystis pneumonia: A systematic review. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rivera D, Ferrajoli A. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Curr Oncol Rep 2022. [PMID: 35366167 DOI: 10.1007/s11912-022-01261-9] [Reference Citation Analysis]
11 Echavarria I, Carrión Galindo JR, Corral J, Diz Taín MP, Henao Carrasco F, Iranzo González-Cruz V, Mielgo-Rubio X, Quintanar T, Rivas Corredor C, Pérez Segura P. SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021). Clin Transl Oncol 2022;24:724-32. [PMID: 35230619 DOI: 10.1007/s12094-022-02800-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Classen AY, Sandherr M, Vehreschild JJ, von Lilienfeld-toal M. Infektionsmanagement in der Hämatologie und Onkologie. Onkologe 2022;28:349-360. [DOI: 10.1007/s00761-022-01120-z] [Reference Citation Analysis]
13 Vehreschild J. Infektionen und Infektionsprophylaxe. Therapie-Handbuch - Onkologie und Hämatologie 2022. [DOI: 10.1016/b978-3-437-23824-6.00018-3] [Reference Citation Analysis]
14 Takeda K, Harada S, Hayama B, Hoashi K, Enokida T, Sasaki T, Okamoto K, Nakano K, Ohkushi D. Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center. BMC Cancer 2021;21:987. [PMID: 34479519 DOI: 10.1186/s12885-021-08727-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Classen AY, Vehreschild JJ. 32/w mit geplanter Induktionstherapie bei neu diagnostizierter akuter lymphatischer Leukämie. Onkologe 2021;27:33-37. [DOI: 10.1007/s00761-021-00979-8] [Reference Citation Analysis]